Priothera Announces First Patients Enrolled in Pivotal MO-TRANS Global Phase IIb/III Study with Mocravimod as an Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Priothera announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase IIb/III study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant.
[British Journal of Cancer] The immunoproteasome subunit LMP7 was silenced by using gene knockout or inhibited by the epoxyketone inhibitor ONX 0914 in a mouse castration-resistant prostate cancer (CRPC) tumor graft model and in interferon-γ-pretreated human CRPC cell lines in vitro.
[British Journal of Cancer] 582 mCRPC patients undergoing first-line abiraterone therapy from four institutions were sorted by three phases: discovery, training, and validation.
[International Journal of Radiation Oncology*Biology*Physics] Researchers performed an international multi-institutional retrospective study of 277 men with metachronous oligometastatic castration-sensitive prostate cancer who underwent targeted DNA sequencing of their primary/metastatic tumor.